Source MDx Liquidating Assets | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) — Source Precision Medicine, dba SourceMDx, said today that it has assigned all its assets to Joseph Finn of accounting firm Finn, Warnke & Gayton for liquidation.

Source MDx has gone out of business and its intellectual property and patents will be sold at a sealed bid sale on April 29 at noon. The liquidation is being conducted for the benefits of Source MDx's creditors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.